Akciğerin Nöronedokrin Tümörleri
Özet
Akciğer nöroendokrin tümörleri (NET), nadir görülen, nöroendokrin farklılaşma ve genellikle yavaş klinik seyir gösteren malign neoplazmalardır. Tüm akciğer tümörlerinin %1-2'sini oluşturan bu hastalık, düşük dereceli iyi diferansiye "tipik" ve orta dereceli "atipik" tümörler olarak sınıflandırılır. Akciğer NET'leri çoğunlukla proksimal hava yollarında yerleşir ve öksürük, hemoptizi veya tekrarlayan pnömoni gibi tıkayıcı semptomlarla kendini gösterir; periferik lezyonlar ise genellikle asemptomatik soliter nodül olarak saptanır. Tanıda bilgisayarlı tomografi ve bronkoskopik biyopsiler öne çıkarken, evreleme için TNM sistemi kullanılır. Lokalize hastalıkta birincil tedavi yaklaşımı cerrahi rezeksiyondur ve tipik NET'lerde operasyon sonrası prognoz mükemmeldir. İnoperabl, ilerlemiş veya somatostatin reseptör pozitif metastatik vakalarda somatostatin analogları (oktreotid/lanreotid), everolimus, radyoetiketli peptit reseptör radyoligand tedavileri (Lutesyum Lu-177) ve sitotoksik kemoterapi rejimleri gibi sistemik tedavi seçenekleri devreye girer. Ayrıca, preinvaziv bir lezyon kabul edilen DIPNEHH tablosunda da benzer şekilde somatostatin analogları tercih edilmektedir.
Lung neuroendocrine tumors (NET) are rare malignant neoplasms characterized by neuroendocrine differentiation and typically indolent clinical behavior. Accounting for approximately 1-2% of all lung malignancies, they are classified into low-grade, well-differentiated "typical" and intermediate-grade "atypical" tumors. Lung NETs predominantly arise in proximal airways, presenting with obstructive symptoms such as cough, hemoptysis, or recurrent pneumonia, whereas peripheral lesions frequently appear as asymptomatic solitary nodules. Computed tomography and bronchoscopic biopsies are key for diagnosis, and staging relies on the TNM system. For localized disease, surgical resection is the preferred therapeutic approach, yielding an excellent prognosis in typical NETs. In inoperable, advanced, or somatostatin receptor-positive metastatic cases, systemic options including somatostatin analogs (octreotide/lanreotide), everolimus, radiolabeled peptide receptor radioligand therapies (Lutetium Lu-177), and cytotoxic chemotherapy regimens are utilized. Furthermore, somatostatin analogs are also preferred in managing DIPNECH, which is recognized as a preinvasive precursor lesion.
Referanslar
Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008; 113:2655.
Hassan MM, Phan A, Li D, et al. Risk factors associated with neuroendocrine tumors: A U.S.-based case-control study. Int J Cancer. 2008; 123:867.
WHO Classification of Tumours of the Lung, Pleura, Thymus, and Heart, 4th ed, Travis WD, Brambilla E, Burke AP, et al. (Eds), IARC, Lyon. 2015.
Rugge M, Fassan M, Clemente R, et al. Bronchopulmonary carcinoid: phenotype and long-term outcome in a single-institution series of Italian patients. Clin Cancer Res. 2008; 14:149.
Nassar AA, Jaroszewski DE, Helmers RA, et al. Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: a systematic overview. Am J Respir Crit Care Med. 2011; 184:8.
Fischer S, Kruger M, McRae K, et al. Giant bronchial carcinoid tumors: a multidisciplinary approach. Ann Thorac Surg. 2001; 71:386.
Scanagatta P, Montresor E, Pergher S, et al. Cushing's syndrome induced by bronchopulmonary carcinoid tumours: a review of 98 cases and our experience of two cases. Chir Ital. 2004; 56:63.
Mengoli MC, Rossi G, Cavazza A, et al. Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) Syndrome and Carcinoid Tumors With/Without NECH: A Clinicopathologic, Radiologic, and Immunomolecular Comparison Study. Am J Surg Pathol. 2018; 42:646.
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls (Accessed on May 18, 2022).
Baudin E, Caplin M, Garcia-Carbonero R, et al. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32:439.
Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors? J Clin Oncol. 2007; 25:1967.
Morandi U, Casali C, Rossi G. Bronchial typical carcinoid tumors. Semin Thorac Cardiovasc Surg. 2006; 18:191.
Fink G, Krelbaum T, Yellin A, et al. Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest. 2001; 119:1647.
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls (Accessed on May 18, 2022).
Baudin E, Caplin M, Garcia-Carbonero R, et al. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32:439.
Singh S, Bergsland EK, Card CM, et al. Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. J Thorac Oncol. 2020; 15:1577.
Fischer S, Kruger M, McRae K, et al. Giant bronchial carcinoid tumors: a multidisciplinary approach. Ann Thorac Surg. 2001; 71:386.
Yao JC, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016; 387:968.
Granberg D, Eriksson B, Wilander E, et al. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol. 2001; 12:1383.
Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 Trial of (177)Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017; 376:125.
FDA approval announcement for lutetium Lu 177 dotatate available online at https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm594043.htm (Accessed on January 29, 2018).
Chauhan A, Ramirez RA. Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) and the Role of Somatostatin analogs: A Case Series. Lung. 2015; 193:653.
